Šalis: Izraelis
kalba: hebrajų
Šaltinis: Ministry of Health
ESOMEPRAZOLE
TARO INTERNATIONAL LTD, ISRAEL
A02BC05
טבליה
ESOMEPRAZOLE 40 MG
פומי
מרשם נדרש
ASTRA ZENECA AB., SWEDEN
ESOMEPRAZOLE
ESOMEPRAZOLE
Nexium tablets are indicated for: Gastroesophageal reflux disease (GERD): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD). In combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylory associated ulcers. - Healing of gastric ulcers associated with NSAID therapy. - Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk.Prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
2021-05-31
Page 1 of 7 1986 – " ) ( 20 " : 20 " ) ( esomeprazole 20 mg as magnesium trihydrate) ) 40 " : 40 " ) ( esomeprazole 40 mg as magnesium trihydrate) ) : 2 " " 6 ." " . . . , . . . 1 . ? , 20 " - 40 " : • . . • ( _Helicobacter pylori_ .) , . • ( NSAIDs ,) .) ( • , ( NSAIDs ) , .) ( • , . , 20 " : • . . • ( _Helicobacter_ _pylori_ .) , . , 40 " : • . . : .) ( 2 . : • ( 6 .)" " • ) ( ( , , , .) • ( - HIV .) Page 2 of 7 : • . • . • . • ( Chromogranin A ) . . , , : • • • • ) ( ( ,) . , , , . ( ) ( ) . , , . , , . ( 4 .) .) ( , , , , . . ) ( , . 12 . / , , , . ( - HIV .) : • ( - HIV ) • ) ( • , ) ( • ) ( • , ) ( • , ( ) • ( ) . , • • ( – ) Page 3 of 7 • ) ( • ) ) • ( .) , • ) ( • ( ) • ) ( ' ) ) ) ( , . . , , . . , . . , . ( 4 ) . . , ) ( . - , . - 1 ( 23 ." " )" 3 . ? . . . • ,) ( . • . , .) ( , . : 18 : • , 40 " 4 . 4 . • 20 . " • , 20 . " , , 20 . " • . , : • 20 . " • , , . NSAIDS :) ( • 20 " 4 8 . Page 4 of 7 NSAIDS :) ( • 20 . " - : • 40 " 4 . 12 : • , 40 " 4 . 4 . • 20 " . • , 20 . " • . , : • 20 " . • . , , • . • . • . . ( pellets coated ) . . • , ( .) ( .) 30 . . . – . • , . . . . , . , . , , . . ! . . . , 4 . . , . . : Page 5 of 7 • , . 1,000 . • , , , , – . 1,000 . • . , , , . . ) ( ת ת ,רפ ל ת ר - , ' רפ . 10,000 . - 10 • • : , , , • • - 100 • • ( ) • , ( " )" , • ) ( • • • ) ( , • , ( ) - 1,000 • – , , • – , • , , • • • ( ) • • • , , • • • • • - 10,000 • , ) ( • • , ( ) • , Page 6 of 7 • . , , ( - , ' , ) • • • ( ) • : , . , , , , . . . . • ) ( • , . , , ) ( . . , , . , " ( " www.health.gov.il ) , : https://sideeffects.health.gov.il 5 . ? • ! . / . • ( (exp. date . . : • C ° 25 . 6 . : Microcrystalline cellulose, methacrylic acid ethyl acrylate copolymer (1:1), sugar spheres, hypromellose, talc, triethyl citrate, hyprolose, crospovidone, macrogol, titanium dioxide (E 171), glycerol mon Perskaitykite visą dokumentą